Tocolytic oxytocin receptor antagonists

Details Tocolytic oxytocin receptor antagonists Tocolytic oxytocin receptor antagonists

1994-03-24

1995-11-07

Tsang, Cecilia

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C07D27300, C07D41300, C07D45100

Patent

active

054647886

ABSTRACT:
Compounds of the formula X--Y--R, or the pharmaceutically acceptable salts and esters thereof, wherein X is ##STR1## Y is --SO.sub.2 --, --(CH.sub.2).sub.p -- or --CO--(CH.sub.2).sub.p --; R is unsubstituted or substituted phenyl where said substitutents are one or more of R.sup.5, R.sup.6 or R.sup.7 ; R.sup.1 is hydrogen, cyano, phenyl,--CONHR.sup.2, --CONR.sup.2 R.sup.2, --(CH.sub.2).sub.m --OR.sup.2, --(CH.sub.2).sub.p --S(O).sub.r --R.sup.2, --(CH.sub.2).sub.m --CO.sub.2 R.sup.2, --(CH.sub.2).sub.m --N.sub.3, --(CH.sub.2).sub.m --NH.sub.2 or --(CH.sub.2).sub.m --NR.sup.2 R.sup.2 ; R.sup.2 is hydrogen, C.sub.3-8 cycloalkyl or C.sub.1-5 alkyl; R.sup.5 and R.sup.6 are each independently selected from hydrogen, C.sub.1-5 alkoxy, halogen or --(CH.sub.2).sub.n --N(R.sup.2)--C(O)--R.sup.18 ; R.sup.7 is hydrogen or ##STR2## R.sup.11 is selected from hydrogen, C.sub.1-5 alkylcarbonyl, ##STR3## or substituted C.sub.1-5 alkyl wherein said alkyl substituent is unsubstituted, mono-, di- or tri-substituted pyridyl wherein said substitutents on said pyridyl are independently selected from halogen, C.sub.1-5 alkyl or C.sub.1-5 alkoxyl; R.sup.13 is unsubstituted or substituted C.sub.1-10 alkyl wherein the substituent is selected from --N(R.sup.2).sub.2, --NHR.sup.2 or imidazolyl; R.sup.14 and R.sup.15 are each independently selected from C.sub.1-5 alkyl, C.sub.1-5 alkoxy or halogen; R.sup.16 is hydrogen or oxo; R.sup.18 is C.sub.1-5 alkoxyl, unsubstituted or substituted C.sub.1-5 alkyl where said substituent is Het, unsubstituted or substituted C.sub.2-5 alkenyl where said subsituent is Het or Het; Het is benzimidazolyl, carboxymethyl-substituted benzimidazolyl or indolyl; m is an integer of from 1 to 5; p is an integer of from 1 to 3; and r is an integer of from 0 to 2. Such compounds as useful as oxytocin and vasopressin receptor antagonists.

REFERENCES:
patent: 4087425 (1978-05-01), Garcia et al.
patent: 4147870 (1979-04-01), Garcia et al.
patent: 4894386 (1990-01-01), Brown et al.
patent: 5091387 (1992-02-01), Evans et al.
patent: 5204349 (1993-04-01), Bock et al.
D. J. Pettibone, et al., Drug Dev. Res. (1993) 30, 129-142, entitled L-368,899, A Potent Orally Active Oxytocin Antagonist For Potential Use In Preterm Labor.
B. E. Evans, et al., J. Med. Chem. (1993) 36, 3993-4005, entitled Nanomolar-Affinity, Non-Peptide Oxytocin Receptor Antagonists.
M. G. Bock, et al., Vasopressin (1993), J. Libbey Eurotext, pp. 539-547.
P. D. Williams, et al., J. Med. Chem. (1994) 37, 565-571.
D. J. Pettibone, et al., Reg. Peptides (1993) 45, 289-293, entitled Development and Pharmacological Assessment of Novel Peptide and Nonpeptide Oxytocin Antagonists.
B. E. Evans, et al., J. Med. Chem. (1992) 35, 3919-3927, entitled Orally Active, Nonpeptide Oxytocin Antagonists.
D. J. Pettibone, et al., J. Pharm. Exp. Ther. (1992) 264, 308-314, entitled Identification of an Orally Active, Nonpeptide Oxytocin Antagonist.

Affiliated with

Also associated with

Rating

Tocolytic oxytocin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tocolytic oxytocin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tocolytic oxytocin receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-197023